Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Phase 1 Recruiting
102 enrolled
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
Phase 1 Completed
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Phase 1 Terminated
35 enrolled 28 charts
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
Phase 1 Completed
21 enrolled
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
Phase 1 Completed
12 enrolled
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
Phase 1 Completed
18 enrolled
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Phase 1 Completed
22 enrolled
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
Phase 1 Completed
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
Phase 1 Terminated
129 enrolled
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
Phase 1 Withdrawn
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors
Phase 1 Completed
94 enrolled
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
Phase 1 Completed
72 enrolled
Cilengitide in Treating Children With Refractory Primary Brain Tumors
Phase 1 Completed
24 enrolled
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
Phase 1 Completed
45 enrolled
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors
Phase 1 Unknown
24 enrolled
Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma
Phase 1 Unknown
48 enrolled
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Phase 1 Completed
20 enrolled
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Phase 1 Completed
60 enrolled
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
Phase 1 Completed
25 enrolled
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
Phase 1 Completed
36 enrolled
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
Phase 1 Completed
30 enrolled
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
Phase 1 Completed
70 enrolled
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
75 enrolled
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
Phase 1 Completed
30 enrolled
ABT-751 in Treating Young Patients With Refractory Solid Tumors
Phase 1 Completed
90 enrolled
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
Phase 1 Completed
26 enrolled
Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors
Phase 1 Completed
32 enrolled
MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer
Phase 1 Terminated
33 enrolled
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors
Phase 1 Completed
42 enrolled
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
Phase 1 Terminated
19 enrolled
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Phase 1 Completed
26 enrolled
SU5416 in Treating Children With Recurrent or Progressive Brain Tumors
Phase 1 Terminated
33 enrolled
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
Phase 1 Completed
53 enrolled
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
Phase 1 Completed
28 enrolled